Biotechnology - Janssen-Cilag

Filter

Current filters:

Janssen-Cilag

Popular Filters

NZ’s PHARMAC awards sole supply to Eprex to Janssen-Cilag

NZ’s PHARMAC awards sole supply to Eprex to Janssen-Cilag

05-08-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has awarded sole subsidised supply status in…

BiotechnologyErythropoiesis-stimulating agentserythropoietinJanssen-CilagJohnson & JohnsonNew ZealandOncologyPricing

Janssen’s hepatitis C drug Olysio cleared in EU

16-05-2014

Janssen-Cilag International, a subsidiary of US health care giant Johnson & Johnson, says that its next…

Anti-viralsBiotechnologyEuropeJanssen-CilagJohnson & JohnsonOlysioRegulation

Janssen’s Vokanamet approved in EU for adults with type 2 diabetes

28-04-2014

The European Commission has approved US health care giant Johnson & Johnson subsidiary Janssen-Cilag’s…

BiotechnologyDiabetesEuropeJanssen-CilagJohnson & JohnsonRegulationVokanamet

Janssen-Cilag files European approval of combination medicine for HIV-1

16-10-2013

US health care giant Johnson & Johnson subsidiary Janssen-Cilag International NV has submitted a Marketing…

Anti-viralsBiotechnologycobicistatDarunavirEuropeGilead SciencesJanssen-CilagJohnson & JohnsonPharmaceuticalRegulation

Janssen files for European approval of hep C candidate simeprevir

25-04-2013

Janssen-Cilag International, a European subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ),…

Anti-viralsBiotechnologyEuropeJanssen-CilagJohnson & JohnsonPharmaceuticalRegulationsimeprevir

Back to top